TWST Earnings Prediction
The chart below shows how TWST performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TWST sees a +1.54% change in stock price 10 days leading up to the earnings, and a +1.84% change 10 days following the report. On the earnings day itself, the stock moves by +2.09%. This data can give you a slight idea of what to expect for the next quarter's release.
TWST Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
84.71M
26.53%
3.98%
Gross Margin
45.13%
23.21%
4.23%
Operating Margin
-42.55%
-38.89%
-21.20%
Net Margin
-40.91%
-40.78%
-61.05%
EPS
-0.59
-27.16%
-59.86%
No Data Available
TWST Earnings Analysis
Twist Bioscience Corporation Common Stock Corporation (TWST.O) Earnings Conference Call
Positive
Record Revenue and Margin Growth: Twist delivered record quarterly revenue and margin growth, ending the year with a strong cash balance.
Performance Exceeds Guidance: We exceeded our guidance in every metric, including total revenue, gross margin, capital expenditure and ending cash balance.
Consistent Revenue Increase: We increased revenue for the seventh quarter in a row, reporting $84.7 million, an increase of 27% year-over-year and 4% sequentially.
Revenue Increase of 28%: For the year, we reported $330 million in revenue, an increase of 28% over fiscal 2023.
Quarterly Gross Margin Performance: Gross margin for the quarter came in ahead of our guidance at 45.1%.
Negative
Adjusted EBITDA Improvement: For fiscal 2024, adjusted EBITDA was a loss of approximately $93.5 million, an improvement of approximately $54 million versus $147.3 million for fiscal 2023.
Operating Cash Flow Comparison: Net cash used in operating activities was $64.1 million compared to $142.5 million for the equivalent 12-month period in 2023.
Operating Expenses Comparison: Operating expenses, excluding cost of revenues for fiscal 2024 were $354 million, including the impairment charge of $45 million in fiscal Q3, compared with $307 million in fiscal 2023.
Gross Margin Improvement Outlook: We expect to see continued improvement in gross margins sequentially throughout the year, but the timing of which is a bit uncertain on some of when they'll actually hit the P&L.
Adjusted EBITDA Loss Forecast: We expect adjusted EBITDA losses of approximately $60 million to $65 million for fiscal 2025, an improvement of approximately $30 million to $35 million versus fiscal 2024.
TWST FAQs
How does TWST typically perform around its earnings report dates?
Is Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TWST Earning Call Sentiment
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
1.0x
00:00
00:00
TWST.O
-1.8%Positive
The earnings call highlights strong financial performance, with a 28% revenue increase and improved gross margins. Despite an EBITDA loss, significant improvement is noted. The Q&A section reveals positive sentiment on product growth and market share expansion. The company maintains a strong cash position and has reduced capital expenditures. While some operational and financial risks exist, the overall outlook is optimistic with a focus on DNA storage as a growth vector. Given the market cap, the stock is likely to experience a positive movement of 2% to 8%.
